Jansen N. Seheult , 1, 2 Michelle N. Stram, 1 Jason Sperry, 3, 4 Philip C. Spinella, 5 Darrell J. Triulzi, 1, 2 and Mark H. Yazer 1, 2 BACKGROUND: There are multiple approaches to the blood product and fluid resuscitation of a bleeding trauma patient. An in silico model of different trauma resuscitation strategies was constructed to predict their effects on the volumes of the different body fluid compartments and on several important hemostatic factors.
STUDY DESIGN AND METHODS:
This multicompartment dynamic deterministic model comprised four interconnected modules (hemostatic, resuscitation, body fluid compartment, and dilutional coagulopathy). The model was divided into five resuscitation phases with simulations using six different resuscitation strategies: whole blood (WB) only, conventional component therapy (CCT) only or 10 units of WB followed by CCT, with either 1 L of crystalloid or 1.5 units of WB or red blood cells in the prehospital phase.
RESULTS:
At the end of the simulations using 1 L of crystalloid fluids in the prehospital resuscitation phase, the use of WB led to a 1.4 g/dL higher hemoglobin concentration, 32 mg/dL higher fibrinogen concentration, and 0.9 L lower total extracellular fluid volume compared to CCT. Prehospital blood product transfusion in place of crystalloid resulted in higher hemoglobin and fibrinogen concentrations and a lower international normalized ratio throughout the resuscitation regardless of the resuscitation strategy used. Throughout both the prehospital crystalloid and prehospital blood product transfusion simulations, the hemoglobin and fibrinogen concentrations and platelet counts were higher, and the international normalized ratio was lower, when WB was used compared to CCT.
CONCLUSIONS: This model predicted improved
hemostatic factor levels and a smaller total extracellular fluid volume volume when WB was transfused instead of CCT to bleeding trauma patients.
C
rystalloid fluids used to be the initial resuscitation fluid of choice for trauma patients with severe bleeding. It was believed that maintaining vascular patency and stabilizing the patient's blood pressure with these fluids would avoid the perceived adverse effects of transfusing blood products while allowing the patient's own red blood cells (RBCs) to deliver oxygen to the damaged tissues. 1 However, the acidic nature of "normal" saline had not been appreciated and the potentially beneficial effect of permissive hypotension was not widely practiced. [2] [3] [4] More recently, an increasing body of evidence has demonstrated that aggressive resuscitation with crystalloid fluids might actually be detrimental to trauma patients, [5] [6] [7] [8] [9] [10] [11] [12] and so modern trauma resuscitation protocols minimize their use. Crystalloid fluids are, from a transfusion perspective, non-oxygen carrying and nonhemostatic. Thus, the current approach to resuscitating trauma patients involves early intervention with blood products that can help achieve these ends. 13 However, not all blood products contain the same quantity of non-oxygen-carrying, nonhemostatic fluids that keep them anticoagulated and/or extend their shelf life. In a whole blood (WB) collection, 500 mL of WB is added to 70 mL of citrate-phosphate-dextrose (CPD) solution. 14 A unit of WB thus contains 70 mL of non-oxygen-carrying, nonhemostatic fluid insofar as CPD solution does not support hemostasis nor does it carry oxygen. If the WB unit is manufactured into components, the resulting plasma and platelet (PLT) units will contain approximately 48 mL and 14 mL of CPD solution, respectively. The RBC unit that is made from a WB donation would contain the remaining 8 mL of CPD solution. Furthermore, 110 mL of additive solution (AS) is commonly added to an RBC unit to extend its shelf life; this AS, like CPD, is also a non-oxygen-carrying, nonhemostatic fluid. Thus, an AS-RBC unit contains approximately 120 mL of non-oxygen-carrying, nonhemostatic fluid.
Understanding the composition of blood components is important when planning a trauma resuscitation strategy for severely bleeding patients, as the amount of non-oxygen-carrying, nonhemostatic fluid that is administered can vary significantly depending on the components chosen. A fixed ratio resuscitation strategy using a 1:1:1 (RBC: plasma: WB-derived PLT equivalent) protocol of conventional components would provide 180 mL of non-oxygen-carrying, nonhemostatic anticoagulant/preservative solution per round of components. In contrast, if a unit of WB were used as the resuscitation fluid, then only 70 mL of non-oxygencarrying, nonhemostatic fluid would be provided per unit. For example, a patient who receives 10 units each of RBCs, plasma, and platelets will receive 1800 mL of non-oxygencarrying, nonhemostatic solution compared to 700 mL if 10 WB units had been administered.
There has been renewed interest in the use of WB during civilian damage control resuscitation, with the majority of centers in a recent survey choosing to adopt a combined approach of using a limited number of WB units early in the resuscitation followed by conventional blood components. 15 The goal of this study was to perform an in silico analysis of the quantity and distribution of the non-oxygen-carrying, nonhemostatic fluids that are administered when different blood components are used in a massive transfusion and to model the effect that these fluids would have on various important laboratory parameters in hemorrhaging trauma patients.
MATERIALS AND METHODS

In silico model description, assumptions, and initial parameters
This in silico analysis was based on the multicompartment dynamic deterministic model of a massively bleeding adult trauma patient developed by Hirshberg et al. 16 and was implemented in open source software (R version 3.4.2, Comprehensive R Archive Network). 17 Briefly, the model comprised four interconnected modules: a hemostatic module, resuscitation module, body fluid compartment module, and dilutional coagulopathy module. The model was divided into five phases: an initial injury phase (minutes 1-10), a prehospital resuscitation phase (minutes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , an emergency department (ED) resuscitation phase (minutes 31-60), an operating room (OR) resuscitation phase (minutes 61-160), and a recovery phase (minutes 161-240).
The duration of the initial injury phase and prehospital resuscitation phase were based on local experience and data from a randomized trial conducted at a Level 1 US civilian trauma center. 18 
Hemostatic module
The hemostatic module simulated changes in the bleeding rate and systolic blood pressure (SBP) that occurs with ongoing hemorrhage. Traumatic injury with bleeding at an initial rate of 135 mL/min started at 1 minute. The bleeding rate then varied primarily with changes in the SBP for the next 160 minutes, at which time surgical hemostasis was achieved. The bleeding rate subsequently fell to 0 mL/min over the next 80 minutes and the simulation ended at 240 minutes ( Fig. 1) . Similar to the model developed by Hirshberg et al., 16 the following assumptions were made regarding the bleeding rate: the bleeding was arterial; the vascular defect remained constant until surgical hemostasis was achieved and was not reduced by clot formation or vasoconstriction; the effects of changes in blood viscosity on the rate of bleeding and on arterial pressure were not accounted for; the sympathetic response did not account for any effects of pain or drugs; and the bleeding rate was not affected by the platelet count, fibrinogen concentration, hematocrit, or international normalized ratio (INR). The SBP during this simulation was a nonlinear function of the total blood volume, that is, the sum of the RBC compartment and the total PV compartment, which included any non-oxygen-carrying, nonhemostatic fluids (redistributed body water, crystalloid, CPD and AS). In addition to being dependent on the SBP, the bleeding rate was modified by an empiric hemostatic mechanism to account for vasoconstriction and increased total vascular resistance, which curtailed bleeding during severe hypotension in order to avoid unrealistic SBPs and in order to achieve the target ED admission SBP at 30 minutes as shown in Table 1B . This target SBP was derived from a cohort of 40 civilian trauma patients who received 10 or more RBC and/or WB units at the authors' Level 1 trauma center. Initial parameters for other important assumptions in this model are shown in Table 1 . The R markdown file and output for the six different simulations are provided in Appendices S2 and S3, available as supporting information in the online version of this paper.
Apart from loss due to bleeding, RBCs, plasma (including fibrinogen), and PLT were also consumed during clot formation; consumed plasma was converted to intravascular colloid since it became non-oxygen-carrying, nonhemostatic fluid but still retained oncotic pressure. The initial consumption rate and the rate of change of the consumption rate over time were adjusted such that the ED admission parameters (at 30 minutes) shown in Table 1B were achieved (see Appendix S1, Methods, available as supporting information in the online version of this paper, for further details).
Resuscitation module
A summary of the number of blood products transfused and volume of crystalloid fluid infused during each resuscitation phase for all six simulations is shown in Table 2 .
For both the crystalloid fluids and blood products in the prehospital resuscitation phase of the simulations, the following assumptions were made regarding the composition of the transfused blood components Resuscitation strategies where crystalloid fluids were administered in the prehospital phase
Resuscitation strategies using WB only, CCT only, or 10 units of WB followed by CCT (WB + CCT) were compared in three simulations. In these simulations, no treatment was administered during the initial injury phase (minutes 1-10), simulating the time taken for rescue to arrive; this was followed by the prehospital resuscitation phase (minutes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , during which approximately 1 L of crystalloid was infused at a rate of 50 mL/min; this was followed by blood product administration from 30 minutes onward once the patient had arrived at the hospital. A graphic representation
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Bleeding rate SBP showing the rectangular pulse wave functions for the volumes of crystalloid, RBCs, plasma, and PLTs administered over time during these three simulations is depicted in Appendix S1, Fig. S1 , available as supporting information in the online version of this paper. Further details about the rate of blood product transfusion in the ED resuscitation, OR resuscitation, and recovery phases in these three prehospital crystalloid simulations are provided in Appendix S1, Methods, available as supporting information in the online version of this paper.
Resuscitation strategies where blood products were administered in place of crystalloid fluids in the prehospital (PH) phase
In addition to the three simulations described above where 1 L of crystalloid fluids was administered in the prehospital resuscitation phase, the effects of transfusing blood products (1.5 units of WB or 1.5 units of RBCs) instead of the crystalloid fluids in the prehospital phase were also evaluated in three additional simulations. For the purposes of these simulations, the remaining half of the RBC or WB unit that had been started in the PH phase was the first component administered when the patient arrived at the ED. After the prehospital phase, the same three resuscitation strategies described above were then simulated; these simulations are referred to as WB-PH (prehospital), CCT-PH, and WB + CCT-PH. A graphic representation showing the rectangular pulse wave functions for the volumes of crystalloid, RBCs, plasma, and PLTs administered over time during these three simulations is depicted in Appendix S1, Fig. S2 , available as supporting information in the online version of this paper. Further details about the rate of blood product transfusion in the ED resuscitation, OR resuscitation, and recovery phases in these three prehospital blood product transfusion simulations are provided in the Appendix S1, Methods, available as supporting information in the online version of this paper.
Body fluid compartment module
The following body fluid compartments were modeled: total body water (TBW), intracellular fluid (ICF), RBC compartment volume (RBCF), non-RBC intracellular fluid (NRBCF), extracellular fluid (ECF), plasma volume (PV), and interstitial fluid (ISF) volume. 21, 22 The equations used to derive these fluid compartments, as well as their assigned initial parameters, are shown in Table 1A . A separate functional plasma compartment (PC), calculated by subtracting from the PV the infused non-oxygen-carrying, nonhemostatic fluids and the free water that entered the plasma compartment from the ISF and RBC compartments, was used to derive the plasma dilution factor (PC/PV). The initial osmolarity of all body compartments was assumed to be 300 mOsm/L or 0.3 mOsm/mL. The increase in fluid compartment osmoles with infusion of crystalloid or blood components was determined by multiplying the osmolarity of the component by the volume infused. The model accounted for (1) changes in osmolarity and fluid volumes in the various compartments based on the osmolarity gradients between pairs of compartments, (2) metabolism of infused dextrose, (3) transcapillary diffusion of free water based on Starling's law for the transcapillary pressure gradient, 21 (4) solute-solvent coupling, whereby solute transfer from the PV to the ISF was accompanied by free water movement, 23 and (5) refilling of the PV from the ISF compartment via the lymphatic circulation. 24 Further details about the modeled changes in osmolarity and fluid volume in the body compartments are provided in Appendix S1, Methods, available as supporting information in the online version of this paper.
Dilutional coagulopathy module
The hemoglobin concentration was calculated by dividing the total quantity of circulating hemoglobin in the RBCs by the total blood volume, i.e. the sum of the RBC compartment and the total PV compartment, which included any non-oxygen-carrying, nonhemostatic fluids (redistributed body water, crystalloid, CPD and AS). The uncorrected PLT count was derived by dividing the total circulating pool of PLTs by the total blood volume; an adjustment function created by Hirshberg et al. 16 was applied, which corrected PLT concentrations by up to 30% above the level predicted by dilution alone, to account for PLT recruitment from the spleen and other sites. 16 The prothrombin time (PT) was derived from the % plasma dilution (i.e., PC/PV) versus PT from a PT-dilution curve generated using laboratory data. Further details about the PT dilution curve and calculation of the INR from the PT are provided in Appendix S1, Methods, available as supporting information in the online version of this paper. The fibrinogen concentration was calculated by dividing the total quantity of circulating fibrinogen by the total PV compartment, which included any nonoxygen-carrying, nonhemostatic fluids (redistributed body water, crystalloid, CPD and AS 
RESULTS
Simulations where crystalloid fluids were administered in the prehospital phase The lowest hemoglobin and fibrinogen concentrations, lowest PLT count, and highest INR achieved at any time during the WB and CCT simulations are shown in Table 3A . There were shorter critical intervals for INR, fibrinogen level, and PLT count (Table 3B) in the WB simulation versus the CCT simulation and a trend toward higher hemoglobin and fibrinogen levels and a lower INR at the end of the WB simulation compared to that at the end of the CCT simulation (Table 3C ). The lowest hemoglobin concentration (i.e., the nadir) at any point in the simulation was 1.0 g/dL higher in the WB simulation compared to the CCT simulation (Table 3A) and by the end of the simulation, the hemoglobin was 1.4 g/dL higher in the WB simulation compared to CCT simulation (Table 3C ). The lowest fibrinogen concentration at any point in the simulation was 18 mg/dL higher in the WB simulation compared to the CCT simulation (Table 3A) and the critical interval for fibrinogen was 17 minutes in the WB simulation compared with 107 minutes in the CCT simulation (Table 3B) ; by the end of the simulation, the fibrinogen concentration was 32 mg/dL higher in the WB simulation compared to CCT simulation (Table 3C ). The highest INR that was reached in the WB simulation was 2.5 compared to 3.0 in the CCT simulation (Table 3A) 212 minutes in the CCT simulation (Table 3B) . Especially early in the patient's in-hospital resuscitation, the PLT count was more pulsatile and frequently fell below 50 × 10 9 /L in the CCT simulation (Fig. 2C) , with a nadir of 16 × 10 9 /L and a critical interval for PLT count of 22 minutes (Table 3B) , while the nadir in the WB simulation was about 71 × 10 9 /L (Table 3A) . For the WB + CCT simulation, in which 10 units of WB were transfused followed by CCT, the trends of the hemostatic parameters mirrored those observed in the WB simulation during the period where WB was being administered (Figs. 2 and 3) . However, from minute 110 onward when CCT was transfused, the values of these parameters rapidly approached and then paralleled the values observed for the CCT simulation. The lowest hemoglobin and fibrinogen concentrations, the lowest PLT count, and the highest INR that were reached for the WB + CCT simulation were similar to those observed in the WB simulation (Table 3A) .
By the end of the recovery phase, that is, the end of the simulation (minute 240), the ISF compartment in the CCT simulation was 0.6 L larger compared to the WB simulation, and 0.4 L larger than the WB + CCT simulation. The total ECF volume, that is, the total PV plus the ISF volume, was 0.9 L and 0.5 L higher in the CCT simulation compared to the WB and WB + CCT simulations, respectively (Table 3C) .
Simulations where blood products were administered in place of crystalloid fluids in the prehospital (PH) phase For these three simulations where blood products were transfused in place of crystalloid fluids in the prehospital phase, the trends in hemoglobin concentration, INR, fibrinogen concentration, PLT count, functional PC, total PV, and ISF compartment volumes for the WB-PH, CCT-PH, and WB + CCT-PH resuscitation strategies are shown in Figs. 2 and 3 .
The lowest hemoglobin and fibrinogen concentrations, lowest PLT count, and highest INR achieved at any time during the WB-PH and CCT-PH simulations are shown in Table 3A . As in the simulations where crystalloid fluids were administered in the prehospital phase, there were shorter critical intervals for INR, fibrinogen level, and PLT count (Table 3B) in the WB-PH simulation versus the CCT-PH simulation, and there was a trend toward higher hemoglobin and fibrinogen levels and a lower INR at the end of the WB-PH simulation compared to that at the end of the CCT-PH simulation (Table 3C ). The lowest hemoglobin concentration at any point in the simulation was 1.6 g/dL higher in the WB-PH simulation compared to the CCT-PH simulation (Table 3A) and by the end of the simulation, the hemoglobin concentration was 1.1 g/dL higher in the WB-PH simulation compared to CCT-PH simulation (Table 3C ). The lowest fibrinogen concentration at any point in the simulation was 41 mg/dL higher in the WB-PH simulation compared to the CCT-PH simulation (Table 3A) and the critical interval for fibrinogen was 0 minutes in the WB-PH simulation compared with 44 minutes in the CCT-PH simulation (Table 3B) ; by the end of the simulation, the fibrinogen concentration was 38 mg/dL higher in the WB-PH simulation compared to CCT-PH simulation (Table 3C ). The highest INR that was reached in the WB-PH simulation was 1.6 compared to 2.2 in the CCT-PH simulation (Table 3A) , and the critical interval for the INR was 31 minutes in the WB simulation compared with 196 minutes in the CCT simulation (Table 3B ). The PLT count was more pulsatile and frequently fell below 50 × 10 9 /L in the CCT-PH simulation (Fig. 2C) , with a nadir of 23 × 10 9 /L and a critical interval for PLT count of 18 minutes (Table 3B) , while the nadir in the WB-PH simulation was 94 × 10 9 /L (Table 3A) .
Similar to the simulations in which crystalloid fluids were administered in the prehospital phase, in the WB + CCT-PH simulation where 10 units of WB were transfused starting in the prehospital phase followed by CCT, the trends for the above-mentioned hemostatic parameters mirrored those observed in the WB-PH simulation during the period where WB-PH was being administered. However, from minute 100 onward, when CCT was transfused, the values of these parameters rapidly approached and then paralleled the values observed for the CCT-PH simulation (Figs. 2 and 3) . The lowest hemoglobin and fibrinogen concentrations that were reached for the WB + CCT-PH simulation were lower than those for the WB-PH simulation but higher than those for the CCT-PH simulation (Table 3A ). The highest INR that was reached for the WB + CCT-PH simulation was similar to that for the WB-PH simulation, while the lowest PLT count that was reached for the WB + CCT-PH simulation was similar to that for the CCT-PH simulation (Table 3A) .
By the end of the recovery phase, that is, the end of the simulation (minute 240), the ISF compartment in the CCT-PH simulation was 0.6 L larger compared to the WB-PH simulation, and 0.3 L larger than the WB + CCT-PH simulation. The total ECF volume, that is, the total PV plus the ISF volume, was 0.9 L and 0.4 L higher in the CCT-PH simulation compared to the WB-PH and WB + CCT-PH simulations, respectively (Table 3C) .
Comparison of the effects of crystalloid administration versus blood product administration in the prehospital resuscitation phase
Comparing the simulations in which crystalloid fluids were administered prehospital with the simulations in which blood products were transfused in the prehospital phase (PH), for example, comparing WB to WB-PH, the differences in hemostatic parameters at the end of the simulations were generally less than 10% (Table 3C ). The lowest hemoglobin and fibrinogen concentrations, the lowest PLT counts, and the highest INRs that were reached at any time during the simulations were worse in the prehospital crystalloid fluid administration simulations compared to the simulations where blood products were administered in the prehospital phase (Table 3A) . Similarly, comparing the WB to WB-PH simulations, the CCT to the CCT-PH simulations, and the WB + CCT to WB + CCT-PH simulations, the critical intervals for fibrinogen and INR were always shorter in duration when blood products were transfused in the prehospital resuscitation phase compared to crystalloid (Table 3B) ; the ISF and ECF volume differences at the end of simulation (minute 240) between the prehospital crystalloid simulations and the prehospital transfusion simulations(PH) were 200 mL or less (Table 3C) .
DISCUSSION
In this in silico model of a massively transfused trauma patient, the use of CCT during the resuscitation was associated with the infusion of a larger quantity of non-oxygen-carrying, nonhemostatic fluids, resulting in a greater dilutional effect on the hemoglobin, plasma, and PLT as well as leading to a larger total ECF compartment volume compared to the model where exclusively WB was transfused. In particular when blood products were transfused instead of crystalloid fluids in the prehospital resuscitation phase, the use of WB resulted in a hemoglobin concentration greater than 10 g/dL, fibrinogen greater than 150 mg/dL, PLT count greater than 50 × 10 9 /L, and INR less than 1.6 for a longer period of time compared to the CCT simulation (Figs. 2 and 3 and Table 3B ). Resuscitation with CCT was also associated with wide fluctuations in the PLT count and INR, which could be detrimental to achieving hemostasis in an actual patient. In fact, extrapolating from retrospective data that showed increased odds of mortality in trauma patients with an admission PLT count of between 0 and 50 × 10 /L) may be associated with increased mortality among CCT recipients. 29 Retrospective data suggest that a PLT count of less than 50 × 10 9 /L is a sensitive predictor of microvascular bleeding, and expert consensus is that the PLT count should be maintained above the critical level of 50 × 10 9 /L in the acutely bleeding patient. 27, 28 Although the evidence is weak, recent massive transfusion guidelines also recommend maintaining higher levels of fibrinogen (>150 mg/dL) 26 and while most of the literature has associated an admission INR greater than 1.5 with trauma-induced coagulopathy and worse clinical outcomes, 25 it is also possible that the duration of time spent at an INR in the critical range is also detrimental. This study also modeled the effects of replacing crystalloid solutions in the prehospital resuscitation phase with blood products, either 1.5 units of WB or 1.5 units of RBCs only (as prehospital plasma transfusion is not yet common in the United States). When blood products were transfused during the prehospital resuscitation phase, there was a blunting of the rise in the INR, and higher hemoglobin and fibrinogen concentration nadirs compared to the simulations that used crystalloid fluids in the prehospital phase. Thus, the results of these simulations mirror closely the real-world experience of improved outcomes associated with prehospital blood product resuscitation. 30, 31 At the end of the simulations (minute 240), however, there were very few differences between the crystalloid and prehospital transfusion (PH) simulations for each of the three resuscitation strategies (WB only, CCT only, or WB + CCT). As most trauma patients who die do so in the first 3 hours following admission, 32, 33 interventions that prevent derangement of coagulation early in the resuscitation might be beneficial in improving mortality. However, very little of the crystalloid fluid remained in the ECF compartment by the end of the simulation due to ongoing bleeding and fluid redistribution. It is interesting to note how quickly the values of most of the parameters in the WB-only simulations began to approach those observed in the CCT simulations once WB transfusion was discontinued and CCT transfusions were commenced. The main reason for this confluence of values was the extra 110 mL of AS that accompanied every AS-1 RBC unit that was transfused; depending on the simulation, there were either 10 or 12 RBC units that were transfused in the WB + CCT simulations between the time that conventional components were initiated and the cessation of transfusion at the end of the simulation. These RBC units provided between 1100 and 1320 mL of non-oxygen-carrying, nonhemostatic AS that would not have been transfused if WB had been transfused for the duration of the resuscitation. It has been demonstrated that transfusing relatively small quantities of lowtiter group O WB with a titer of anti-A and -B less than 50 is a serologically safe intervention in trauma patients [34] [35] [36] ; it is likely that transfusing larger quantities of low-titer group O WB, or low-titer group O WB with higher titers of anti-A and -B, will be similarly safe in this setting. However, whether WB should be used as the sole blood product for the entire resuscitation or whether goal-directed resuscitation using conventional components should be implemented during the resuscitation remains an unanswered question.
The administration of crystalloid fluids in the prehospital setting might cause adverse effects in the recipient. Retrospective data suggest that infusion of more than 500 mL of crystalloid fluid in the prehospital resuscitation phase may be associated with an increased risk of mortality and acute coagulopathy (INR >1.5) in patients without prehospital hypotension. 37 Furthermore, a large database study found a correlation between increased ventilator days, as well as intensive care unit and hospital length of stay, and the amount of crystalloids infused in the first 24 hours after injury. 5 Thus, due to the potentially deleterious consequences of administering these fluids, which also might include clot disruption, dilutional coagulopathy, and proinflammatory effects on the endothelial glycocalyx, 4,10,11 there has been a paradigm shift toward the early use of blood products and limiting the amount of crystalloid fluids administered in the prehospital resuscitation of trauma patients. 38 CPD and the various ASs that are found in blood components have different compositions and higher osmolarities compared to normal saline and other crystalloid solutions.
1,39 Thus, while the adverse effects following the administration of crystalloid fluids-especially normal saline-are beginning to be appreciated, 7, [40] [41] [42] it is not clear if the non-oxygen-carrying, nonhemostatic fluids that are transfused along with the blood products would similarly contribute to these adverse effects. Nevertheless, at a minimum, the non-oxygen-carrying, nonhemostatic fluids that are transfused along with the blood products would contribute to the overall fluid load that the patient receives. Because these fluids do not assist in the resuscitation by transporting oxygen or promoting hemostasis, minimizing the volume transfused seems like an important end. Furthermore, CPD and AS can contribute to or exacerbate the interstitial edema associated with increased capillary permeability in trauma leading to complications such as tissue injury, multiorgan failure, acute respiratory distress syndrome, and delayed wound healing. 43 While blood components are now preferred to crystalloid solutions partly because of the decreased risk of interstitial edema, these simulations highlight the effect of different blood component resuscitation strategies on ISF volumes, with a decreased ISF volume observed in the WB models compared to the CCT models, regardless of whether crystalloids were administered in the prehospital setting. This finding suggests that the majority of non-oxygen-carrying, nonhemostatic fluid transfused in the blood products, if not lost due to bleeding, is redistributed from the PV compartment to the ISF compartment over time, suggesting that resuscitation strategies that minimize the volume of non-oxygen-carrying, nonhemostatic fluid that is administered could benefit trauma patients. This study has several limitations. It is important to note that the generalizability of these simulations to actual patients may be limited primarily because the simulations could not account for the potential effect of subhemostatic concentrations of fibrinogen, plasma coagulation factors, and PLTs on the bleeding rate and the length of time that the patient was bleeding, that is, the time to achieve complete hemostasis in the OR. As a definite relationship between subhemostatic concentrations of these parameters and bleeding rate is unknown, it was not possible to model their effects on the bleeding rate. Perhaps the patients with subhemostatic values would have required additional blood products; this would have increased the amount of nonoxygen-carrying, nonhemostatic fluids that would have been administered, especially among recipients of CCT. Similarly, other parameters that might impact the bleeding rate or the time to achieve complete hemostasis but whose effects are difficult to quantify, such as the effect of low hematocrit on hemostasis, 44 acidosis, hypothermia, the potentially enhanced hemostatic effect of the cold stored PLTs in the WB, 45 or PLT inhibition in trauma, 46, 47 were also not included in the model. In addition, the initial bleeding rate and duration of the five resuscitation phases used in the simulations were based on expert opinion and might vary among centers or among patients.
The volumes of the various blood components used in these simulations were based on a random sampling of stored blood products from the local blood collection center, and the PLT content of the WB unit was based on local quality control data obtained from fresh WB units after leukoreduction. In addition, each blood component that was administered in these simulations contained exactly the same quantity of plasma, RBCs, and PLTs, while actual components have some heterogeneity in their contents. 48 This deterministic model, therefore, did not account for variations in blood product content during storage or after modifications such as pathogen reduction, and thus the results of these simulations might have been different if components with higher or lower plasma volumes, hemoglobin content, or PLT counts were administered. Furthermore, these simulations used AS-1 RBC units, which do not contain additional citrate anticoagulant. The non-oxygen-carrying, nonhemostatic fluid composition of the various ASs used for RBC storage vary considerably, and AS-3, in particular, contains citrate anticoagulant, 29 which could theoretically adversely affect in vivo coagulation; the significance of administering citrate in blood components, however, is difficult to predict because most of the infused citrate will be rapidly metabolized in vivo with the release of the chelated calcium. 49, 50 Infused citrate may be more deleterious in patients with decreased metabolism, as has been described in traumatic hemorrhage, 51 but these effects are difficult to model accurately. Finally, there were limited data available to inform the consumption rates of the various hemostatic factors, so the consumption rates and temporal changes in consumption rates were adjusted such that the target ED admission parameters at 30 minutes were achieved. These target admission values were derived from actual patient data, and the results for the simulations, which used crystalloid in the prehospital phase, were within 10% of the target admission parameters; fine-tuning of the model assumptions by targeting these admission parameters created a more objective model that more closely reflected the real-world setting. The redistribution half-life of the various fluids was based on data from healthy volunteers, and it is possible that the half-life of redistribution is different in trauma patients, including those under general anesthesia, based on data on the redistribution of other crystalloid solutions, such as Ringer's lactate, in general surgical patients. 36 In addition, the rate at which the infused dextrose in the CPD and additive solution was metabolized was also based on data from healthy individuals, and the half-life may, in fact, be different in bleeding trauma patients. 52 These simulations also did not account for the elimination of osmoles and fluid from the kidneys, gastrointestinal tract, and skin. Finally, the aim of these simulations was not to predict clinical outcomes such as mortality in massively transfused trauma patients, but instead to assess the changes in hemostatic parameters and body fluid compartments using different fluid and blood product resuscitation strategies.
This study modeled the dilutional effects on hemostatic factors in the blood and the changes in body fluid compartments associated with the transfusion of large quantities of non-oxygen-carrying, nonhemostatic fluids during a massive transfusion. Conventional component therapy was associated with a greater dilution of hemostatic factors and a greater volume of interstitial fluid compared to WB due primarily to the extra 110 mL of AS in each of the transfused RBC units. Prehospital blood product transfusion in place of crystalloid fluids led to improved levels of important hemostatic parameters, such as coagulation factors, fibrinogen, PLTs, and RBCs, early in the resuscitation, when these factors are most needed.
